Biogen Inc. (BIIB)Healthcare | Drug Manufacturers - General | Cambridge, United States | NasdaqGS
177.35 USD
+1.33
(0.756%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 179.50 +2.15 (1.212%) ⇧ (April 17, 2026, 6:51 p.m. EDT) Short-term: ★★★☆☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 11, 2026, 3:48 p.m. EDT
Biogen Inc. (BIIB) presents a mixed investment opportunity. Short-term traders may find the recent price movements and options activity intriguing, with potential for momentum plays or buy-the-dip opportunities. However, the lack of dividend payouts makes it less appealing for income-focused investors. For long-term investors, the strong fundamentals, positive analyst recommendations, and recent acquisition activity suggest a solid growth potential. However, the recent revenue decline and high debt-to-equity ratio should be considered. Overall, BIIB is a stock with potential for growth but requires careful consideration of the risks involved. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.052283 |
| MSTL | 0.060564 |
| AutoARIMA | 0.061350 |
| AutoETS | 0.061350 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 80% |
| H-stat | 0.19 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.457 |
| Excess Kurtosis | -0.89 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 36.466 |
| Revenue per Share | 67.513 |
| Market Cap | 26,027,626,496 |
| Trailing P/E | 20.20 |
| Forward P/E | 11.17 |
| Beta | 0.16 |
| Profit Margins | 13.07% |
| Website | https://www.biogen.com |
As of April 11, 2026, 3:48 p.m. EDT: The options activity indicates mixed sentiment. There is a notable increase in open interest and volume for both calls and puts, particularly around strikes near the current price of $172.97. The ATM IV is relatively low, suggesting limited volatility expectations, but there are spikes in IV for certain strikes, indicating potential for significant price movements. The presence of major OI walls and volume spikes around specific strikes suggests that traders are positioning for potential upward or downward moves. Overall, the options data suggests a cautious outlook with potential for both bullish and bearish scenarios.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.51103103 |
| Address1 | 225 Binney Street |
| All Time High | 480.18 |
| All Time Low | 0.354167 |
| Ask | 186.26 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 2.1 - Buy |
| Average Daily Volume10 Day | 1,414,980 |
| Average Daily Volume3 Month | 1,251,793 |
| Average Volume | 1,251,793 |
| Average Volume10Days | 1,414,980 |
| Beta | 0.162 |
| Bid | 169.39 |
| Bid Size | 1 |
| Board Risk | 2 |
| Book Value | 124.365 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 177.35 |
| Current Ratio | 2.679 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 178.405 |
| Day Low | 175.69 |
| Debt To Equity | 36.466 |
| Display Name | Biogen |
| Earnings Call Timestamp End | 1,777,464,000 |
| Earnings Call Timestamp Start | 1,777,464,000 |
| Earnings Timestamp | 1,777,465,800 |
| Earnings Timestamp End | 1,777,465,800 |
| Earnings Timestamp Start | 1,777,465,800 |
| Ebitda | 3,603,699,968 |
| Ebitda Margins | 0.36436 |
| Enterprise To Ebitda | 8.011 |
| Enterprise To Revenue | 2.919 |
| Enterprise Value | 28,869,525,504 |
| Eps Current Year | 15.64873 |
| Eps Forward | 15.87613 |
| Eps Trailing Twelve Months | 8.78 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 186.2336 |
| Fifty Day Average Change | -8.883591 |
| Fifty Day Average Change Percent | -0.047701333 |
| Fifty Two Week Change Percent | 51.103104 |
| Fifty Two Week High | 202.41 |
| Fifty Two Week High Change | -25.059998 |
| Fifty Two Week High Change Percent | -0.1238081 |
| Fifty Two Week Low | 115.25 |
| Fifty Two Week Low Change | 62.100006 |
| Fifty Two Week Low Change Percent | 0.5388287 |
| Fifty Two Week Range | 115.25 - 202.41 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 685,114,200,000 |
| Float Shares | 146,275,692 |
| Forward Eps | 15.87613 |
| Forward P E | 11.170858 |
| Free Cashflow | 1,981,887,488 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 7,500 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,775,001,600 |
| Gross Margins | 0.78946 |
| Gross Profits | 7,808,200,192 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0016500001 |
| Held Percent Institutions | 0.98572 |
| Implied Shares Outstanding | 146,758,528 |
| Industry | Drug Manufacturers - General |
| Industry Disp | Drug Manufacturers - General |
| Industry Key | drug-manufacturers-general |
| Ir Website | http://www.biogenidec.com/INVESTORS.aspx?ID=5494 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 979,776,000 |
| Last Split Factor | 3:1 |
| Long Business Summary | Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Biogen Inc. |
| Market | us_market |
| Market Cap | 26,027,626,496 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_29726 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | 1,292,899,968 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 25,832,436,098 |
| Number Of Analyst Opinions | 30 |
| Open | 176.29 |
| Operating Cashflow | 2,204,600,064 |
| Operating Margins | 0.19641 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 3.65 |
| Phone | 617 679 2000 |
| Post Market Change | 2.149994 |
| Post Market Change Percent | 1.2122886 |
| Post Market Price | 179.5 |
| Post Market Time | 1,776,466,306 |
| Previous Close | 176.02 |
| Price Eps Current Year | 11.333188 |
| Price Hint | 2 |
| Price To Book | 1.4260443 |
| Price To Sales Trailing12 Months | 2.6315517 |
| Profit Margins | 0.13071999 |
| Quick Ratio | 1.697 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | buy |
| Recommendation Mean | 2.13889 |
| Region | US |
| Regular Market Change | 1.33 |
| Regular Market Change Percent | 0.755597 |
| Regular Market Day High | 178.405 |
| Regular Market Day Low | 175.69 |
| Regular Market Day Range | 175.69 - 178.405 |
| Regular Market Open | 176.29 |
| Regular Market Previous Close | 176.02 |
| Regular Market Price | 177.35 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 1,062,805 |
| Return On Assets | 0.0614 |
| Return On Equity | 0.07394 |
| Revenue Growth | -0.071 |
| Revenue Per Share | 67.513 |
| Sand P52 Week Change | 0.36506534 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 2 |
| Shares Outstanding | 146,758,528 |
| Shares Percent Shares Out | 0.026099999 |
| Shares Short | 3,826,441 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 4,202,912 |
| Short Name | Biogen Inc. |
| Short Percent Of Float | 0.0337 |
| Short Ratio | 3.96 |
| Source Interval | 15 |
| State | MA |
| Symbol | BIIB |
| Target High Price | 275.0 |
| Target Low Price | 150.0 |
| Target Mean Price | 207.694 |
| Target Median Price | 203.5 |
| Total Cash | 3,815,699,968 |
| Total Cash Per Share | 26.0 |
| Total Debt | 6,657,600,000 |
| Total Revenue | 9,890,599,936 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 8.78 |
| Trailing P E | 20.199318 |
| Trailing Peg Ratio | 3.6496 |
| Triggerable | 1 |
| Two Hundred Day Average | 161.48895 |
| Two Hundred Day Average Change | 15.861053 |
| Two Hundred Day Average Change Percent | 0.09821758 |
| Type Disp | Equity |
| Volume | 1,062,805 |
| Website | https://www.biogen.com |
| Zip | 2,142 |